scholarly journals Evaluating peripheral retinal vascularization and rate of recurrence after intravitreal injection of ranibizumab as a primary treatment for retinopathy of prematurity

2020 ◽  
Vol 113 (4) ◽  
pp. 125
Author(s):  
MostafaM El Manhaly ◽  
OssamaA El Hadad ◽  
HeshamF Goweini ◽  
AhmedA Souka
Keyword(s):  
Intravitreal Injection ◽  
Retinopathy Of Prematurity ◽  
Primary Treatment ◽  
Retinal Vascularization

INTRAVITREAL RANIBIZUMAB INJECTION AS TREATMENT IN PATIENTS WITH TYPE 1 RETINOPATHY OF PREMATURITY

2021 ◽  
pp. 13-15
Author(s):  
Kalishankar Das ◽  
Athokpam Poireiton ◽  
Sneha Bhowmick
Keyword(s):  
Cohort Study ◽  
Intravitreal Injection ◽  
Retinopathy Of Prematurity ◽  
Positive Response ◽  
Primary Treatment ◽  
Intravitreal Ranibizumab ◽  
Response Group ◽  
Type 1 Rop

Aim: To investigate the anatomic outcomes of patients treated with intravitreal ranibizumab in the treatment of type 1 retinopathy of prematurity (ROP). A prospective cohort study was done including 100 eyes of Material And Method: 60 patients with type 1 ROP treated with intravitreal injection of ranibizumab (IVR) (0.25 mg/ 0.025 ml) as primary treatment from June 2018 to November 2019 over a period of 18 months. The anatomic outcomes were analyzed and follow-up were done upto 6 months. There were a Result: total of 94 eyes (94.0%) in the positive response group and 6 eyes (6.0%) in the negative/no response group after IVR. Within the positive response group, 49 eyes (52.13%) were in the regression without laser subgroup, and 45 eyes (47.87%) were in the regression with laser subgroup. Conclusion: Intravitreal injection of ranibizumab seemed to be effective in treating patients with type 1 ROP.

Effect of Intravitreal Injection as a Primary Treatment in Cystoid Macular Edema after Cataract Surgery

2012 ◽  
Vol 53 (3) ◽  
pp. 428 ◽  
Author(s):  
Joo Yeon Kim ◽  
Joung Mok Kim ◽  
Young Ju Lew ◽  
Chul Gu Kim ◽  
Sung Won Cho ◽  
...  
Keyword(s):  
Cataract Surgery ◽  
Macular Edema ◽  
Intravitreal Injection ◽  
Cystoid Macular Edema ◽  
Primary Treatment

The first experience of application of vessel endothelium growth factor inhibitor ranibizumab in complex therapy of retinopathy of premature in URFO in SAHI of the Sverdlovsk region MСMC «Bonum»

2021 ◽  
pp. 360-362
Author(s):  
M.A. Kariakin ◽  
◽  
E.A. Stepanova ◽  
S.A. Korotkikh ◽  
N.S. Timofeeva ◽  
...  
Keyword(s):  
Retinal Detachment ◽  
Intravitreal Injection ◽  
Laser Treatment ◽  
Retinopathy Of Prematurity ◽  
Laser Coagulation ◽  
Complete Regression ◽  
Complex Treatment ◽  
Partial Regression ◽  
Factor Inhibitor ◽  
Retinal Adhesion

Material and methods. The study included 16 patients (31 eyes). Types and terms of treatment. Stage I in the treatment of ROP, laser coagulation of the avascular areas of the retina was performed in three patients with aggressive posterior ROP (4 eyes, 12.9%). In all patients, the progression of the disease was noted. Intravitreal injection of ranibizumab was performed in the period from 8 to 16 weeks (10.5±2.0 weeks), PCV from 32.3 to 39.6 weeks (37.0±1.8 weeks). Result. After laser treatment and IVI of ranibizumab, 11 patients (31 eyes, 81.6%) showed regression of the disease. In 5 patients (6 eyes, 19.4%) - progression. If the ROP progressed, a 25G or 27G lenssparing vitrectomy was performed. Complete regression of ROP was achieved in one patient (1 eye, 16.7%). Partial regression was observed in two patients (2 eyes, 33.3%). In two patients (3 eyes, 50%), the disease progressed to stage 5 with the development of total retinal detachment. Conclusion. As a result of the complex treatment of severe forms of the active stage of retinopathy of prematurity in the regional children's ophthalmological center MKMC "Bonum" in Yekaterinburg, the following data were obtained: complete regression with retinal adhesion is observed in 12 patients (26 eyes, 83.4%), of which in one patient (1 eye, 3.2%) regression was achieved after vitrectomy. Partial regression with the formation of a peripheral retinal detachment after vitrectomy was achieved in two patients (two eyes - 6.5%). Progression of retinopathy of prematurity to stage V with the development of total retinal detachment in two patients (3 eyes, 9.6%). Complex treatment of severe stages of active ROP using laser treatment, IVI and vitrectomy allows to preserve vision in 90.4% of patients. Key words: retinopathy of prematurity; intravitreal injection; laser coagulation of the retina; vitrectomy.

Efficacy of ultra-low-dose (0.1 mg) ranibizumab intravitreal injection for treatment of prethreshold type 1 retinopathy of prematurity: A case series

2018 ◽  
Vol 30 (1) ◽  
pp. 40-47 ◽  
Author(s):  
Islam SH Ahmed ◽  
Ahmed MA Hadi ◽  
Hassan H Hassan
Keyword(s):  
Side Effects ◽  
Intravitreal Injection ◽  
Retinopathy Of Prematurity ◽  
Large Scale ◽  
Low Dose ◽  
Case Series ◽  
Results Of Treatment ◽  
Case Series Study ◽  
Systemic Side Effects

Aim: To report the results of treatment of type 1 prethreshold retinopathy of prematurity using intravitreal injection of ultra-low dose of ranibizumab (0.1 mg in 0.01 mL). Design: A retrospective observational case series study. Methods: Review of files of eligible infants who received this form of treatment to determine the outcome of treatment and any associated ocular or systemic side effects. Results: The study included 24 eyes of 12 preterm infants with mean gestational age of 29.75 ± 1.54 weeks and mean birth weight of 1074.58 ± 320.59 g. A total of 22 eyes (91.67%) had zone II disease while 2 eyes of one infant (8.33%) had zone I disease. All cases showed regression of the signs of the active retinopathy of prematurity with complete retinal vascularization. None of the cases required retreatment. Three eyes developed ocular complications. Apart from mild feeding intolerance that lasted for 24 h after injection in one infant, none of the cases developed systemic side effects. Conclusion: Intravitreal injection of ultra-low-dose ranibizumab showed promising efficacy and good ocular safety. However, further large-scale studies are required to give stronger evidence about the efficacy and safety of ultra-low-dose ranibizumab.

scholarly journals Intravitreal Injection of Bevacizumab for Retinopathy of Prematurity in an Infant with Peters Anomaly

2014 ◽  
Vol 5 (3) ◽  
pp. 318-324 ◽  
Author(s):  
Tsuyoshi Minami ◽  
Kazuki Kuniyoshi ◽  
Shunji Kusaka ◽  
Koji Sugioka ◽  
Hiroyuki Sakuramoto ◽  
...  
Keyword(s):  
Intravitreal Injection ◽  
Retinopathy Of Prematurity ◽  
Peters Anomaly

scholarly journals Short-Term Changes in Intraocular Pressure After Intravitreal Injection of Bevacizumab for the Treatment of Retinopathy of Prematurity

2019 ◽  
Vol Volume 13 ◽  
pp. 2445-2449
Author(s):  
Shumpei Obata ◽  
Tomoaki Higashiyama ◽  
Taku Imamura ◽  
Masashi Kakinoki ◽  
Takahide Yanagi ◽  
...  
Keyword(s):  
Intraocular Pressure ◽  
Intravitreal Injection ◽  
Retinopathy Of Prematurity ◽  
Short Term

Intravitreal topotecan in the management of refractory and recurrent vitreous seeds in retinoblastoma

2017 ◽  
Vol 102 (4) ◽  
pp. 490-495 ◽  
Author(s):  
Raksha Rao ◽  
Santosh G Honavar ◽  
Vishal Sharma ◽  
Vijay Anand P Reddy
Keyword(s):  
Visual Acuity ◽  
Intravitreal Injection ◽  
Primary Treatment ◽  
Complete Regression ◽  
Intravenous Chemotherapy ◽  
Systemic Complications ◽  
Group D ◽  
Vitreous Seeds

Background/aimTo evaluate the efficacy of intravitreal topotecan for refractory or recurrent vitreous seeds in retinoblastoma.MethodsIntravitreal injection of topotecan hydrochloride (30 µg/0.15 mL) was provided every 3 weeks by the safety enhanced technique.ResultsThe study included 17 consecutive patients with retinoblastoma with refractory or recurrent vitreous seeds. Five eyes (29%) belonged to International Classification of Retinoblastoma group C and 12 eyes (71%) belonged to group D. Primary treatment included triple drug intravenous chemotherapy for a mean of 10 cycles (median, 9 cycles; range, 6–18 cycles). Fifteen patients (88%) had undergone 56 periocular carboplatin injections with a mean of 4 injections (median, 3 injections; range, 1–8 injections), concurrent with intravenous chemotherapy. A total of 53 intravitreal topotecan injections were performed in 17 eyes of 17 consecutive patients with refractory or recurrent vitreous seeds with a mean of 3 injections (median, 3 injections; range, 2–6 injections). Complete regression of vitreous seeds was achieved in 17 of 17 eyes (100%). At a mean follow-up of 23.8 months (median, 24 months; range, 15.1–34.1 months), one eye (6%) with a recurrent retinal tumour needed enucleation, and the rest of the 16 eyes (94%) maintained complete regression. Final visual acuity could be reliably assessed in all 16 eyes (100%), of whom 12 eyes (75%) had visual acuity ≥20/200. None of the patients developed ocular or systemic complications.ConclusionThree-weekly intravitreal topotecan appears effective and safe in controlling focal or diffuse refractory or recurrent vitreous seeds in retinoblastoma.

Sign in / Sign up

Export Citation Format

Share Document